Chronic spontaneous urticaria, treatment with antihistamines

Czech version

Authors: Iva Karlová
Authors‘ workplace: Klinika chorob kožních a pohlavních Fakultní nemocnice a Lékařské fakulty Univerzity Palackého Olomouc
Published in: Čes. slov. Farm., 2024; 73, 13-15
Category: Current Pharmacotherapy
doi: https://doi.org/10.36290/csf.2024.002

Overview

Chronic spontaneous urticaria is characterized by reccurent wheals lasting more than 6 weeks, it can persist for months or years. The disease can lead to a significant worsening in the quality of life. According to recent guidelines second-generation non-sedative antihistamines are the first-line treatment. If the therapeutic effect of the standard dose of antihistamines is insufficient, it is recommended to up-dose to 4-fold.

Keywords:

chronic urticaria, antihistamines, up-dosing.

Sources

1. Zuberbier T, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77:734-766.

2. Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria Allergy Asthma Clin Immunol. 2019,15:56.

3. Bystroň J. Antihistaminika v léčbě alergického zánětu, Remedia. 2014, 25.

4. Holgate St.,Canocica Gw., Simons Fe. et al. Consensus group of new generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;33:1305-1324.

5. Járegui I., Ferrer M., Montoro J. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17:41-52.

6. Ferrer M., Sastre J., Jáuregui I. et al. Effect of antihistamine up-dosing in chronic urticaria. J Investig Allergol Clin Immunol. 2011;21(3):34-39.

7. Weller K, Ardelean E, Scholz E, et al. Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double – blind, Randomized, Single-dose Study. Acta derm venerol. 2013;93:168-174.

8. Staevska M., Popov TA., Kramalimarkova T., et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficultto-treat urticaria. J Allergy Clin Immunol. 2010;125:676-8.

9. Finn AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071-8.

10. Weller K, Church MK, Hawro T, et al. Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. Allergy.2018;73(10):2073-5.

11. Merlos M, Giral M, Balsa D, et al. Rupatidine, a new potent orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997;280:114-121.

12. Giménez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol. 2009; 23:1088-9.

13. Weller K, Ziege C, Staubach P, et al. H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients Perspective of Effectiveness and Side Effects – A Retrospective Survey Study. www.plosone.org. 2011;6(9):e23931.

14. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines , J Clin Psychopharmacol. 2002;22:511-515.

15. Vester JC, Volkerts ER. Antihistamine and driving ability: evidence from on-the road driving studies during normal traffic. Ann Asthma Immunol. 2004;92:294-303.